Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in ...

Grape seed extract—a dietary supplement made from the seeds of wine grapes—has been investigated to see if it can help reduce ...

BERLIN — For men with high-risk biochemically recurrent prostate cancer, adding enzalutamide (Xtandi) to standard androgen ...

A new drug combination cuts the risk of death in people with advanced prostate cancer by 40% over eight years, according to ...

Prostate cancer screening for men over 70 is complex, with current recommendations against routine PSA testing due to slow ...

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...

Key Takeaways Combining enzalutamide with standard hormone therapy cut the risk of prostate cancer death by over 40% in a ...